Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.
Rapisarda A, et al. Among authors: melillo g.
Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.
Mol Cancer Ther. 2009.
PMID: 19584228
Free PMC article.